Brokerages Expect ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Will Post Earnings of -$0.13 Per Share
Wall Street brokerages expect ZIOPHARM Oncology Inc (NASDAQ:ZIOP) to announce earnings per share (EPS) of ($0.13) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for ZIOPHARM Oncology’s earnings, with estimates ranging from ($0.16) to ($0.11). ZIOPHARM Oncology reported earnings of ($0.10) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 30%. The business is expected to report its next earnings results on Tuesday, August 8th.
According to Zacks, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.57) per share for the current fiscal year, with EPS estimates ranging from ($0.75) to ($0.46). For the next financial year, analysts forecast that the firm will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.86) to ($0.45). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Monday, May 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.03. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.71 million. The business’s revenue for the quarter was down 18.8% on a year-over-year basis.
ZIOP has been the topic of several recent research reports. HC Wainwright initiated coverage on shares of ZIOPHARM Oncology in a report on Thursday, June 1st. They set a “buy” rating and a $9.50 target price on the stock. ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, April 26th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $13.00.
Shares of ZIOPHARM Oncology (NASDAQ ZIOP) opened at 6.08 on Monday. The stock’s 50 day moving average is $5.92 and its 200-day moving average is $6.34. ZIOPHARM Oncology has a 52 week low of $4.45 and a 52 week high of $7.88. The company’s market cap is $794.66 million.
Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in ZIOPHARM Oncology by 5.7% in the first quarter. Vanguard Group Inc. now owns 7,310,537 shares of the biotechnology company’s stock worth $46,348,000 after buying an additional 396,678 shares in the last quarter. State Street Corp raised its position in ZIOPHARM Oncology by 0.6% in the first quarter. State Street Corp now owns 4,039,207 shares of the biotechnology company’s stock worth $25,607,000 after buying an additional 22,864 shares in the last quarter. Morgan Stanley raised its position in ZIOPHARM Oncology by 19.5% in the first quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock worth $12,610,000 after buying an additional 324,774 shares in the last quarter. Norges Bank acquired a new position in ZIOPHARM Oncology during the fourth quarter worth about $5,556,000. Finally, Geode Capital Management LLC raised its position in ZIOPHARM Oncology by 3.9% in the first quarter. Geode Capital Management LLC now owns 1,016,427 shares of the biotechnology company’s stock worth $6,444,000 after buying an additional 38,173 shares in the last quarter. 38.05% of the stock is owned by hedge funds and other institutional investors.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.